Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.77
BABY's Cash-to-Debt is ranked lower than
56% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. BABY: 1.77 )
Ranked among companies with meaningful Cash-to-Debt only.
BABY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: No Debt Max: No Debt
Current: 1.77
Equity-to-Asset 0.64
BABY's Equity-to-Asset is ranked higher than
55% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. BABY: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
BABY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.71  Med: 0.82 Max: 0.94
Current: 0.64
-1.71
0.94
Interest Coverage 128.51
BABY's Interest Coverage is ranked higher than
55% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. BABY: 128.51 )
Ranked among companies with meaningful Interest Coverage only.
BABY' s Interest Coverage Range Over the Past 10 Years
Min: 10.45  Med: 100.22 Max: 151.91
Current: 128.51
10.45
151.91
Piotroski F-Score: 7
Altman Z-Score: 5.16
Beneish M-Score: -3.28
WACC vs ROIC
8.36%
13.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 14.47
BABY's Operating Margin % is ranked higher than
79% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. BABY: 14.47 )
Ranked among companies with meaningful Operating Margin % only.
BABY' s Operating Margin % Range Over the Past 10 Years
Min: -4.44  Med: 11.48 Max: 15.75
Current: 14.47
-4.44
15.75
Net Margin % 11.15
BABY's Net Margin % is ranked higher than
79% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. BABY: 11.15 )
Ranked among companies with meaningful Net Margin % only.
BABY' s Net Margin % Range Over the Past 10 Years
Min: -4.8  Med: 7.55 Max: 11.15
Current: 11.15
-4.8
11.15
ROE % 10.62
BABY's ROE % is ranked higher than
72% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. BABY: 10.62 )
Ranked among companies with meaningful ROE % only.
BABY' s ROE % Range Over the Past 10 Years
Min: -4.28  Med: 8.52 Max: 10.62
Current: 10.62
-4.28
10.62
ROA % 8.20
BABY's ROA % is ranked higher than
80% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. BABY: 8.20 )
Ranked among companies with meaningful ROA % only.
BABY' s ROA % Range Over the Past 10 Years
Min: -3.46  Med: 5.94 Max: 8.3
Current: 8.2
-3.46
8.3
ROC (Joel Greenblatt) % 57.75
BABY's ROC (Joel Greenblatt) % is ranked higher than
90% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. BABY: 57.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BABY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.53  Med: 41.37 Max: 57.75
Current: 57.75
-12.53
57.75
3-Year Revenue Growth Rate 1.10
BABY's 3-Year Revenue Growth Rate is ranked lower than
64% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. BABY: 1.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BABY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: 10.65 Max: 38.3
Current: 1.1
-61.9
38.3
3-Year EBITDA Growth Rate 13.20
BABY's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. BABY: 13.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BABY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -88.5  Med: 22.8 Max: 863.2
Current: 13.2
-88.5
863.2
3-Year EPS without NRI Growth Rate 19.80
BABY's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. BABY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BABY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -1.6 Max: 106.2
Current: 19.8
-52.8
106.2
GuruFocus has detected 1 Warning Sign with Natus Medical Inc $BABY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BABY's 10-Y Financials

Financials (Next Earnings Date: 2017-07-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BABY Guru Trades in Q1 2016

Diamond Hill Capital 591,256 sh (+20.51%)
Paul Tudor Jones Sold Out
Ken Fisher 589,433 sh (-0.98%)
Joel Greenblatt 84,563 sh (-53.26%)
Jim Simons 56,945 sh (-58.81%)
» More
Q2 2016

BABY Guru Trades in Q2 2016

Robert Olstein 57,025 sh (New)
Steven Cohen 622,600 sh (New)
Joel Greenblatt 280,046 sh (+231.17%)
Ken Fisher 589,798 sh (+0.06%)
Diamond Hill Capital 591,256 sh (unchged)
Jim Simons Sold Out
» More
Q3 2016

BABY Guru Trades in Q3 2016

Columbia Wanger 265,000 sh (New)
Jim Simons 13,200 sh (New)
Ken Fisher 611,816 sh (+3.73%)
Steven Cohen Sold Out
Diamond Hill Capital 589,744 sh (-0.26%)
Robert Olstein 55,850 sh (-2.06%)
Joel Greenblatt 142,710 sh (-49.04%)
» More
Q4 2016

BABY Guru Trades in Q4 2016

Paul Tudor Jones 16,520 sh (New)
Steven Cohen 74,900 sh (New)
Jim Simons 45,800 sh (+246.97%)
Columbia Wanger 590,825 sh (+122.95%)
Robert Olstein 77,795 sh (+39.29%)
Joel Greenblatt 147,129 sh (+3.10%)
Diamond Hill Capital 589,551 sh (-0.03%)
Ken Fisher 610,049 sh (-0.29%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ITGR, NAS:SPNC, NAS:CNMD, OTCPK:SHHPF, NAS:INGN, NAS:HTWR, NAS:CYNO, NAS:MDXG, NAS:VASC, OTCPK:IOBCF, NAS:CSII, NAS:KTWO, NAS:OFIX, OTCPK:NHNKY, NAS:GNMK, OTCPK:SBMAF, OTCPK:MZRTF, NYSE:CRY, OTCPK:NMRD, NAS:XENT » details
Traded in other countries:NM4.Germany,
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Natus Medical Inc was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The company is a provider of newborn care and neurology healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company offers two product families: Neurology and Newborn Care. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intra-operative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. The company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.

Top Ranked Articles about Natus Medical Inc

Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Largest insider buys for Valvoline, Natus, OPKO and Guess
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purhases is illustrated in the chart below: Read more...
Natus Medical CEO Acquires Shares in Company Insider purchases 10,000 shares
James Hawkins (Insider Trades), president and CEO of Natus Medical Inc. (BABY), acquired 10,000 shares in the company on Sept. 28. The price per share was $38.48 for a total transaction of $384,800. Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.60
BABY's PE Ratio is ranked lower than
58% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. BABY: 29.60 )
Ranked among companies with meaningful PE Ratio only.
BABY' s PE Ratio Range Over the Past 10 Years
Min: 11.26  Med: 35.02 Max: 683.33
Current: 29.6
11.26
683.33
Forward PE Ratio 21.79
BABY's Forward PE Ratio is ranked higher than
58% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.98 vs. BABY: 21.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.60
BABY's PE Ratio without NRI is ranked lower than
54% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. BABY: 29.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
BABY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.26  Med: 35.02 Max: 683.33
Current: 29.6
11.26
683.33
Price-to-Owner-Earnings 22.81
BABY's Price-to-Owner-Earnings is ranked higher than
65% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 30.84 vs. BABY: 22.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BABY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.79  Med: 39.95 Max: 8415
Current: 22.81
18.79
8415
PB Ratio 3.01
BABY's PB Ratio is ranked higher than
53% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. BABY: 3.01 )
Ranked among companies with meaningful PB Ratio only.
BABY' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.46 Max: 5.56
Current: 3.01
0.79
5.56
PS Ratio 3.30
BABY's PS Ratio is ranked lower than
51% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. BABY: 3.30 )
Ranked among companies with meaningful PS Ratio only.
BABY' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.53 Max: 7.26
Current: 3.3
0.95
7.26
Price-to-Free-Cash-Flow 18.20
BABY's Price-to-Free-Cash-Flow is ranked higher than
67% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. BABY: 18.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BABY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.62  Med: 31.88 Max: 490.59
Current: 18.2
12.62
490.59
Price-to-Operating-Cash-Flow 17.36
BABY's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. BABY: 17.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BABY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.17  Med: 25.54 Max: 106.24
Current: 17.36
10.17
106.24
EV-to-EBIT 20.72
BABY's EV-to-EBIT is ranked higher than
52% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. BABY: 20.72 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.3  Med: 23.05 Max: 400.3
Current: 20.72
-29.3
400.3
EV-to-EBITDA 15.90
BABY's EV-to-EBITDA is ranked higher than
50% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. BABY: 15.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 16.85 Max: 5595.8
Current: 15.9
-82.2
5595.8
PEG Ratio 0.15
BABY's PEG Ratio is ranked higher than
97% of the 80 Companies
in the Global Medical Devices industry.

( Industry Median: 2.49 vs. BABY: 0.15 )
Ranked among companies with meaningful PEG Ratio only.
BABY' s PEG Ratio Range Over the Past 10 Years
Min: 0.15  Med: 1.17 Max: 2.38
Current: 0.15
0.15
2.38
Shiller PE Ratio 62.59
BABY's Shiller PE Ratio is ranked lower than
66% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 53.11 vs. BABY: 62.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
BABY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.71  Med: 80.63 Max: 115
Current: 62.59
43.71
115
Current Ratio 5.08
BABY's Current Ratio is ranked higher than
84% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. BABY: 5.08 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.17 Max: 16.01
Current: 5.08
1.41
16.01
Quick Ratio 4.46
BABY's Quick Ratio is ranked higher than
84% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. BABY: 4.46 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 2.57 Max: 15.09
Current: 4.46
1
15.09
Days Inventory 118.78
BABY's Days Inventory is ranked higher than
52% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. BABY: 118.78 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 104.01  Med: 123.48 Max: 132.84
Current: 118.78
104.01
132.84
Days Sales Outstanding 82.81
BABY's Days Sales Outstanding is ranked lower than
67% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. BABY: 82.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 86.98 Max: 112.34
Current: 82.81
81.74
112.34
Days Payable 46.45
BABY's Days Payable is ranked lower than
60% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. BABY: 46.45 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 44.18  Med: 67.82 Max: 92.09
Current: 46.45
44.18
92.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
BABY's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. BABY: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BABY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.4  Med: -3.4 Max: -1.6
Current: -1.6
-185.4
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 79.52
BABY's Price-to-Net-Cash is ranked lower than
91% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.38 vs. BABY: 79.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BABY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.62  Med: 4.71 Max: 82.29
Current: 79.52
1.62
82.29
Price-to-Net-Current-Asset-Value 7.22
BABY's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. BABY: 7.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BABY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.27  Med: 6.58 Max: 12.49
Current: 7.22
1.27
12.49
Price-to-Tangible-Book 5.53
BABY's Price-to-Tangible-Book is ranked lower than
63% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. BABY: 5.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BABY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.19  Med: 4.55 Max: 64.5
Current: 5.53
1.19
64.5
Price-to-Intrinsic-Value-Projected-FCF 1.86
BABY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. BABY: 1.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BABY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.5 Max: 4.31
Current: 1.86
0.8
4.31
Price-to-Median-PS-Value 1.31
BABY's Price-to-Median-PS-Value is ranked lower than
68% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BABY: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BABY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.97 Max: 2.77
Current: 1.31
0.15
2.77
Price-to-Peter-Lynch-Fair-Value 8.75
BABY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. BABY: 8.75 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BABY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.43 Max: 8.99
Current: 8.75
0
8.99
Price-to-Graham-Number 2.70
BABY's Price-to-Graham-Number is ranked lower than
58% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. BABY: 2.70 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BABY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.71  Med: 3.1 Max: 11.38
Current: 2.7
1.71
11.38
Earnings Yield (Greenblatt) % 4.84
BABY's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. BABY: 4.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BABY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 4.2 Max: 20
Current: 4.84
0.2
20
Forward Rate of Return (Yacktman) % 12.57
BABY's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.85 vs. BABY: 12.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BABY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.5  Med: 2.85 Max: 75
Current: 12.57
-1.5
75

More Statistics

Revenue (TTM) (Mil) $381.9
EPS (TTM) $ 1.29
Beta0.85
Short Percentage of Float8.07%
52-Week Range $29.54 - 44.39
Shares Outstanding (Mil)32.87

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 503 523
EPS ($) 1.77 2.23
EPS without NRI ($) 1.77 2.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
22.00%
Dividends per Share ($)
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight Dec 27 2016 
Weekly CEO Buys Highlight Oct 31 2016 
Weekly CEO Buys Highlight Oct 03 2016 
Natus Medical CEO Acquires Shares in Company Sep 29 2016 
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 
Diamond Hill Small Cap Fund Q4 2014 Commentary Mar 17 2015 
Diamond Hill Small Cap Fund Third Quarter Letter Oct 25 2014 
Diamond Hill Capital Comments on Natus Medical Inc Oct 17 2014 
Diamond Hill Small Cap Fund Third Quarter 2014 Commentary Oct 17 2014 
Diamond Hill Capital Comments on Natus Medical Inc Jun 26 2014 

More From Other Websites
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a Class... Mar 28 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Mar 27 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Natus Medical Incorporated of Upcoming... Mar 25 2017
NATUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Mar 24 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Natus... Mar 24 2017
BABY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Mar 24 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical... Mar 24 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Natus Medical Incorporated of Imminent... Mar 23 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical... Mar 23 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Natus... Mar 23 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical... Mar 22 2017
DEADLINE ALERT: Brower Piven Reminds Investors of the March 31, 2017 Deadline in Class Action... Mar 21 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a... Mar 21 2017
NATUS MEDICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits Mar 20 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus... Mar 18 2017
Johnson & Weaver, LLP Files Class Action Suit against Natus Medical Incorporated Mar 18 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Mar 17 2017
Natus Medical Investor Deadline Reminder: Hagens Berman Reminds Investors in Natus Medical of the... Mar 17 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical... Mar 17 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a... Mar 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)